Xultophy 100/3.6 (active ingredients: insulin degludec and liraglutide) subcutaneous injection Initial FDA Approval: 2016 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
Lower inflammation means lower risk of heart attacks, strokes, kidney disease, and possibly better outcomes for people with autoimmune or inflammatory conditions
If you live in Wesley Chapel and youre looking into GLP-1 weight loss injections, telehealth makes the first step simple
It is sold under two brand names
In addition to tracking when your period starts , it can be really helpful to note the duration and heaviness of your flow
Ask your pharmacy whether they are a 503A or 503B facility, whether they comply with current USP 797 standards, and whether they have conducted stability testing specific to their tirzepatide formulation
.jpg)
